SCHEMBL6298751

SCHEMBL6298751

COc1c(CN(C)C)cc(C(C)(C)C)cc1NC(=O)Nc1ccc(Oc2ccncc2)c2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 14/20 0.67
SRC P12931 18/20 0.61
MAPK14 Q16539 18/20 0.61
SYK P43405 14/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14459488 0.88 MAPK14 (0.60) GSK3ASRCMAPK14SYK
SCHEMBL14459485 0.86 MAPK14 (0.60) GSK3ASRCMAPK14SYK
SCHEMBL6298725 0.84 SRC (0.54) GSK3ASRCMAPK14SYK
SCHEMBL14459482 0.83 GSK3A (0.68) GSK3ASRCMAPK14SYK
SCHEMBL6840076 0.83 GSK3A (0.67) GSK3ASRCMAPK14SYK
SCHEMBL6545890 0.82 GSK3A (0.61) GSK3ASRCMAPK14SYK
SCHEMBL16829199 0.80 GSK3A (1.00) GSK3ASRCMAPK14SYK
SCHEMBL6547129 0.80 MAPK14 (0.59) GSK3ASRCMAPK14SYK
SCHEMBL6545985 0.80 GSK3A (0.68) GSK3ASRCMAPK14SYK
SCHEMBL6300858 0.79 GSK3A (0.62) GSK3ASRCMAPK14SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852717-B2 Compounds useful as anti-inflammatory agents BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-02-08 US claimed
EP-1392661-A1 DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2004-03-03 EP claimed
US-20030008868-A1 Compounds useful as anti-inflammatory agents BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-01-09 US claimed
WO-2002092576-A1 DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-11-21 WO claimed
US-6852717-B2 Compounds useful as anti-inflammatory agents BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
EP-1392661-A1 DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2004-03-03 EP disclosed
WO-2002092576-A1 DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008868-A1 Compounds useful as anti-inflammatory agents TNF, MPO, PTGES GSK3A 3334/4885SRC 3231/4885MAPK14 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.